XBRL SEC Pilot Pfizer Inc.

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, J0zvfdT1OvYrPJuH1OAFDNRpQr8yHqCkAm1eqWL2ZtUd5CBE1r3zgcgqZAk7idR4 i8NM0WyN7kM9/V2lOAGP7A== 0000078003-06-000319.txt : 20061130 0000078003-06-000319.hdr.sgml : 20061130 20061130124850 ACCESSION NUMBER: 0000078003-06-000319 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 7 CONFORMED PERIOD OF REPORT: 20061130 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20061130 DATE AS OF CHANGE: 20061130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 061247559 BUSINESS ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 BUSINESS PHONE: 2125732323 MAIL ADDRESS: STREET 1: 235 E 42ND ST CITY: NEW YORK STATE: NY ZIP: 10017 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 8-K 1 k8pfe-20060702.htm XBRL PFIZER 8-K XBRL SEC Pilot Pfizer Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report: November 30, 2006 Date of earliest event reported: November 30, 2006
PFIZER INC. (Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation)	1-3619 (Commission File Number)	13-5315170 (I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017 (Address of principal executive offices) (zip code) (212) 573-2323 (Registrant's telephone number)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions:

[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

Exhibit 100 to this Current Report on Form 8-K contains documents formatted in XBRL (eXtensible Business Reporting Language) with information from Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter ended July 2, 2006, filed with the Securities and Exchange Commission (SEC) on August 11, 2006. The information formatted in XBRL includes the (i) Condensed Consolidated Statements of Income for the three and six months ended July 2, 2006 and July 3, 2005, (ii) Condensed Consolidated Balance Sheets at July 2, 2006 and December 31, 2005, and (iii) Condensed Consolidated Statements of Cash Flows for the six months ended July 2, 2006 and July 3, 2005.

Users of this data are advised pursuant to Rule 401 of Regulation S-T that the financial information contained in the XBRL-Related Documents is unaudited and these are not the official financial statements of Pfizer Inc. as filed with the SEC. The purpose of furnishing these XBRL formatted documents is solely for the purpose of participation in the SEC's voluntary XBRL pilot program to test the related format and technology and, as a result, investors should continue to rely on the official filed version of the furnished documents and not rely on the information in this Current Report on Form 8-K, including Exhibit 100, in making investment decisions.

In accordance with Rule 402 of Regulation S-T, the information in this Current Report on Form 8-K, including Exhibit 100, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d)	Exhibits

	The following exhibits are furnished herewith:

	Exhibit Number	Exhibit Description

	100	The following financial statements from Pfizer Inc.'s Quarterly Report on Form 10-Q for the quarter ended July 2, 2006, filed on August 11, 2006, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Consolidated Statements of Income for the three and six months ended July 2, 2006 and July 3, 2005, (ii) the Condensed Consolidated Balance Sheets at July 2, 2006 and December 31, 2005, and (iii) the Condensed Consolidated Statements of Cash Flows for the six months ended July 2, 2006 and July 3, 2005.

SIGNATURE

Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.


		PFIZER INC.

		By: /s/ Margaret M. Foran
		Margaret M. Foran


Dated: November 30, 2006		Title: Senior Vice President-Corporate Governance
		Associate General Counsel and Corporate Secretary

EXHIBIT INDEX

Exhibit No.		Description

EX-100.INS		XBRL Instance Document

EX-100.SCH		XBRL Taxonomy Extension Schema Document

EX-100.SCH.1		XBRL Schema Supplement Document

EX-100.CAL		XBRL Taxonomy Extension Calculation Linkbase Document

EX-100.LAB		XBRL Taxonomy Extension Label Linkbase Document

EX-100.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

EX-100.INS 2 pfe-20060702.xml XBRL INSTANCE DOCUMENT 0000078003 2005-07-03 unaudited 0000078003 2004-12-31 audited 0000078003 2006-04-03 2006-07-02 unaudited 0000078003 2006-01-01 2006-07-02 unaudited 0000078003 2005-04-04 2005-07-03 unaudited 0000078003 2005-01-01 2005-07-03 unaudited 0000078003 2006-07-02 unaudited 0000078003 2005-12-31 audited xbrli:shares iso4217:USD xbrli:shares iso4217:USD 1602000000 1399000000 1736000000 856000000 1648000000 823000000 6659000000 6804000000 0.38 0.19 0.48 0.24 -369000000 -636000000 232000000 88000000 230000000 125000000 0.03 0.01 0.03 0.02 0.03 0.01 0.03 0.02 1772000000 1757000000 -923000000 -700000000 -53000000 -114000000 -65000000 -31000000 41000000 0 20000000 17000000 3531000000 3375000000 6296000000 2290000000 191000000 88000000 210000000 108000000 1296000000 921000000 90000000 938000000 1213000000 0 1237000000 1369000000 2497000000 2387000000 4000000 1000000 5000000 3000000 4860000000 4495000000 6564000000 5655000000 93000000 45000000 854000000 -198000000 -615000000 -359000000 276000000 -116000000 2903000000 3262000000 -997000000 -887000000 480000000 264000000 567000000 268000000 11589000000 3779000000 510000000 511000000 278000000 318000000

9103000000

9275000000

2073000000

1740000000

479000000

1508000000

-255000000

-1989000000

67759000000

68217000000

117698000000

111550000000

0.51

0.47

0.89

0.33

1808000000

1276000000

2247000000

1921000000

329000000

414000000

439000000

440000000

3639000000

1762000000

3461000000

1790000000

28455000000

20055000000

-931000000

-438000000

10392000000

10369000000

0.51

0.47

0.89

0.33

-2930000000

-3468000000

2000000

-9000000

79000000

326000000

5646000000

2912000000

7353000000

3083000000

0.48

0.46

0.86

0.31

0.48

0.46

0.86

0.31

3618000000

4356000000

26244000000

26134000000

20985000000

21057000000

5478000000

6392000000

51934000000

43061000000

117698000000

111550000000

6347000000

5450000000

-11686000000

-13743000000

4169000000

4322000000

6983000000

9104000000

3763000000

3463000000

6526000000

2415000000

-532000000

-326000000

215000000

219000000

23595000000

11452000000

23488000000

11741000000

2635000000

3019000000

1424000000

1447000000

-3304000000

-2000000000

2681000000

2721000000

169000000

152000000

2000000

1054000000

101000000

14000000

6000000

3000000

12570000000

13239000000

262000000

260000000

513000000

16233000000

16483000000

2111000000

-464000000

1052000000

790000000

-560000000

-248000000

-99000000

-78000000

-7441000000

-5663000000

-22000000

-2000000

-5800000000

-10583000000

3547000000

1830000000

3285000000

1742000000

37608000000

40627000000

568000000

47000000

7431000000

3766000000

7276000000

3881000000

19979000000

12829000000

65764000000

68489000000

46879000000

40994000000

2776000000

2694000000

-39767000000

-41755000000

7445000000

7418000000

7330000000

7305000000

7391000000

7366000000

7298000000

7282000000

262000000

513000000

(a) Exclusive of amortization of intangible assets, except as disclosed in Note12B, Goodwill and Other Intangible Assets: Other Intangible Assets. EX-100.SCH 3 pfe-20060702.xsd XBRL EXTENSION TAXONOMY EX-100.SCH.1 4 pfe-ssu_xbrl.xsd XBRL SCHEMA SUPPLEMENT DOCUMENT EX-100.CAL 5 pfe-20060702_cal.xml XBRL CALCULATION LINKBASE EX-100.LAB 6 pfe-20060702_lab.xml XBRL LABEL LINKBASE Cost of sales Selling, informational and administrative expenses Other assets (including deposits and advances) deferred taxes and deferred charges Other assets, deferred taxes and deferred charges Prepaid Expenses - Total Prepaid Insurance Dividends payable represent dividends declared but not yet paid. Dividends payable Liabilities Discontinued Operations - Current Postretirement benefit obligations Accrued compensation and related items includes accrued employee compensation, accrued payroll taxes, accrued pension, accrued postemployment benefits, accrued postretirement benefits and other related items Accrued compensation and related items Includes minority interest and other noncurrent liabilities. Other noncurrent liabilities Represents the fair value of Pfizer Inc shares owned by the Trust used to fund Pfizer's employee benefit plans. Employee benefit trust, at fair value Income from continuing operations before provision/(benefit) for taxes on income and minority interests Income from discontinued operations-net of tax Income (loss) of a business segment that has been discontinued net of taxes Income/(Loss) from Disposition of Discontinued Operations - Total Cash dividends paid per common share cash dividends paid per common share Restructuring charges are associated with the exit or disposal of an activity, including one-time termination benefits, contract termination costs and other exit costs (e.g., consolidation of facilities). Merger-related costs consist of integration costs directly related to acquisitions and restructuring costs incurred in connection with acquisitions. Restructuring charges and merger-related costs Consists of other current liabilities and deferred income tax liabilities current. Other current liabilities Other (income)/deductions-net Other (income)/deductions-net can include non operating items such as interest income/expense, royalty income, asset impairments, gains/losses on sale of fixed assets, gains/losses on disposals of investments or products. income from continuing operations after provision for taxes and minority interest Income from continuing operations Net cash provided by operating activities Loss from discontinued operations loss from operations of a business segment that has been reported as discontinued operations. cash payments for purchases of property, plant and equipment Purchases of property, plant and equipment Proceeds from redemptions of short-term investments Proceeds from sales of long-term investments Purchases of long-term investments Acquisitions, net of cash acquired Net cash provided by investing activities Cash provided by/(used in) other investing activities, net. Other investing activities Share-based compensation expense Merger-related in-process research and development charges Asset impairment charge Other non-cash adjustments Deferred taxes from continuing operations Proceeds from the sales of businesses, products and product lines Proceeds from Short-Term Borrowings Principal payments on short-term borrowings Proceeds from issuances of long-term debt Principal payments on long-term debt Purchases of common stock Cash dividends paid cash received from stock option exercises and other financing related cash transactions not previously identified Stock option transactions and other Net cash used in financing activities Effect of exchange-rate changes on cash and cash equivalents Cash and cash equivalents at beginning of period cash paid for income taxes Cash paid during the period for income taxes Cash paid during the period for interest amortization of intangible assets Amortization of intangible assets subsidiary income not owned by the consolidating entity, net of taxes Minority interests total of operations and gains/(losses) on sales of discontinued operations. Discontinued operations-net of tax Revenues Research and development expenses Merger-related in-process research and development charges Provision/(benefit) for taxes on income Income/(Loss) from Disposition of Discontinued Operations Gain/(loss) on disposal of discontinued operations net of tax Gains on sales of discontinued operations - net of tax Income from continuing operations per common share-basic Income/(Loss) from Discontinued Operations per Outstanding Share Net income per common share-basic Weighted-average shares used to calculate earnings per common share-basic Income/(loss) from Disposition of Discontinued Operations per Outstanding Share Net income per common share-diluted Weighted-average shares used to calculate earnings per common share-diluted Income from continuing operations per common share-diluted Cash and cash equivalents Accounts receivable, less allowance for doubtful accounts Short-term investments Inventories Assets Discontinued Operations-Current Total current assets Property, plant and equipment, less accumulated depreciation Identifiable intangible assets, less accumulated amortization Total assets Accounts payable Income taxes payable Total current liabilities Long-term debt Pension benefit obligations Deferred taxes Other noncurrent liabilities Total liabilities Preferred stock Common stock Additional paid-in capital Treasury stock Retained earnings Accumulated other comprehensive income Total shareholders' equity Total liabilities and shareholders' equity Purchases of short-term investments Proceeds from sales of other assets Net decrease in cash and cash equivalents Depreciation and amortization Purchases of other assets Cash and cash equivalents at end of period Income/(loss) from discontinued operations per common share basic Discontinued operations-net of tax per common share-basic Income/(loss) from discontinued operations per common share diluted Discontinued operations-net of tax per common share-diluted Assets held for sale Liabilities held for sale and anticipated to be sold within 12 months. Liabilities held for sale Consists of assets of discontinued operations and long-lived assets held for sale that are expected to be disposed of within 12 months or have been disposed of at the financial statement date. Assets of discontinued operations and other assets held for sale Net income Long-term investments and loans consists of (a) investments in nonconsolidated subsidiaries accounted for using the equity and or cost method; (b) debt and equity financial instruments which can include trading securities, held-to-maturity and securities available for sale; (c) long-terms loans with maturities in excess of one year. The portion of long-term loans that is due to be collected within one year is recorded under Short-term loans Long-term investments and loans Short term borrowings have maturities within 12 months, including the portion of long-term debt with maturities within 12 months Short-term borrowings, including current portion of long-term debt Consists of liabilities of discontinued operations and other liabilities held for sale that are expected to be disposed of within 12 months or have been disposed of at the financial statement date. Liabilities of discontinued operations and other liabilities held for sale The net of new short-term borrowings with maturities of 90 days or less and new repayments of short-term borrowings with maturities of 90 days or less, and new short-term borrowings with maturities greater than 90 days. Increase in short-term borrowings, net Non cash charges for intangible asset impairments and associated non-cash charges. Intangible asset impairments and other associated non-cash charges Gains on disposal of investments, products and product lines Gains on disposal of investments, products and product lines Non-cash gains from sales of business segment that has been reported as discontinued operations. Gains on sales of discontinued operations The net change in the beginning and end of period deferred income taxes balances. Other deferred taxes Change in operating assets and liabilities from beginning to end of period. Changes in assets and liabilities (net of businesses acquired and divested) Includes Prepaid expenses and current deferred tax asset. Prepaid expenses are the unamortized costs of rights to receive a service or use a resource. These prepayments include, for example, employee advances, prepaid insurance, prepaid taxes, etc. Prepaid expenses and taxes Short-term loans are those with an original maturity of one year or less. Also included in this account is the portion of long-term loans that are due to be collected within one year. Short-term loans EX-100.PRE 7 pfe-20060702_pre.xml XBRL PRESENTATION LINKBASE -----END PRIVACY-ENHANCED MESSAGE-----